{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:06:53Z","timestamp":1783750013089,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BRAF and MEKis have revolutionized the management of BRAF<jats:sup>V600<\/jats:sup>\u2010mutated melanoma patients. Left ventricular ejection fraction decrease (LVEF\u2010D) related to these treatments has not been thoroughly evaluated to date. The main objective of this study was to describe characteristics of LVEF\u2010D in melanoma patients treated with BRAF and\/or MEKis. Metastatic melanoma patients treated with BRAF and\/or MEKis between March 1, 2012 and May 18, 2018 were included retrospectively (Lyon Sud University Hospital, Hospices Civils de Lyon). LVEF\u2010D was defined as a reduction in LVEF \u226510% from baseline to a value &lt;55%; normalization was defined as a value \u226555%. Among the 88 patients included, 12 (13.6%) experienced a LVEF\u2010D, including 10 grade 2 and 2 grade 3. The median onset of which was 11\u00a0months (IQR [3\u201021]). No patient previously treated with beta\u2010blockers (n\u00a0=\u00a012) experienced a LVEF\u2010D. Analysis of laboratory parameters, electrocardiogram, and transthoracic echocardiography during the follow\u2010up did not find any predictive marker of LVEF\u2010D. All patients who benefited from a specific treatment of LVEF\u2010D had a normalization of LVEF at the end of follow\u2010up. LVEF recovery was significantly better for patients treated with angiotensin converting enzyme inhibitors and beta\u2010blockers than those who did not (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.019). Ophthalmological adverse events were significantly more frequent in patients who experienced a LVEF\u2010D (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.006) and the latter did not influence overall\u2010survival (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.117) or progression\u2010free\u2010survival (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.297). LVEF\u2010D is a common and easily manageable adverse event due to BRAF and MEKis. Its association with ocular toxicity suggests a close ophthalmological monitoring when LVEF\u2010D occurs.<\/jats:p>","DOI":"10.1002\/cam4.2922","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T03:07:00Z","timestamp":1581649620000},"page":"2611-2620","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Left ventricular ejection fraction decrease related to BRAF and\/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis"],"prefix":"10.1002","volume":"9","author":[{"given":"Mathilde","family":"Berger","sequence":"first","affiliation":[{"name":"Service de dermatologie Centre Hospitalier Lyon Sud Hospices Civils de Lyon Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amini\u2010Adl\u00e9","sequence":"additional","affiliation":[{"name":"Service de dermatologie Centre Hospitalier Lyon Sud Hospices Civils de Lyon Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Maucort\u2010Boulch","sequence":"additional","affiliation":[{"name":"Service de Biostatistiques Hospices Civils de Lyon Universit\u00e9 Lyon 1 Lyon France"},{"name":"Laboratoire de Biom\u00e9trie et Biologie Evolutive Universit\u00e9 de Lyon CNRS Equipe Biostatistique\u2010Sant\u00e9 Villeurbanne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Robinson","sequence":"additional","affiliation":[{"name":"Direction de la Recherche Clinique et de l\u2019Innovation Hospices Civils de Lyon Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Thomas","sequence":"additional","affiliation":[{"name":"Service de dermatologie Centre Hospitalier Lyon Sud Hospices Civils de Lyon Pierre\u2010B\u00e9nite France"},{"name":"Centre de Recherche en Canc\u00e9rologie de Lyon Universit\u00e9 de Lyon Universit\u00e9 Claude Bernard Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"Service de dermatologie Centre Hospitalier Lyon Sud Hospices Civils de Lyon Pierre\u2010B\u00e9nite France"},{"name":"Centre de Recherche en Canc\u00e9rologie de Lyon Universit\u00e9 de Lyon Universit\u00e9 Claude Bernard Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-7977","authenticated-orcid":false,"given":"Pierre\u2010Yves","family":"Courand","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon Service de cardiologie H\u00f4pital de la Croix\u2010Rousse et Centre Hospitalier Lyon Sud Lyon France"},{"name":"Universit\u00e9 de Lyon Creatis Umr Inserm U1044 INSA Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"7","volume-title":"Cancer Statistics, 2019","author":"Siegel RL","year":"2019"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5853"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-017-9425-z"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0456"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014566428"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1188\/17.CJON.699-709"},{"key":"e_1_2_9_12_1","first-page":"29","article-title":"BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management","volume":"3","author":"Livingstone E","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1215"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jew082"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx391"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2004.08.030"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu268"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00748-8"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf170"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000130926.51766.CC"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.7588"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2013.12.018"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70409-7"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.973321"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2013.02.008"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.03.095"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.635144"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212352200"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.86.10.1047"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.005"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2010.10.021"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0060"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357060"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-007-0658-z"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00054.2009"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119709"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000038488.38975.1A"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01054.2004"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127126.73759.23"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610906104"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000242"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.06.018"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.82"},{"issue":"959","key":"e_1_2_9_49_1","first-page":"e1","article-title":"Ocular toxicity in metastatic melanoma patients treated with mitogen\u2010activated protein kinase kinase inhibitors: a case series","volume":"160","author":"Niro A","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4213"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.243"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:42:11Z","timestamp":1755582131000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1002\/cam4.2922"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2922","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"2019-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}